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Abstract Recent guidelines of the American Association
for the Study of Liver Diseases, the European Association
for the Study of the Liver, and the Asian Pacific Associa-
tion for the Study of the Liver 2008 update of the ‘‘Asian-
Pacific consensus statement on the management of chronic
hepatitis B’’ offer comprehensive recommendations for the
general management of chronic hepatitis B (CHB). These
recommendations highlight preferred approaches to the
prevention, diagnosis, and treatment of CHB. Nonetheless,
the results of recent studies have led to an improved
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understanding of the disease and a belief that current rec-
ommendations on specific therapeutic considerations,
including CHB treatment initiation and cessation criteria,
particularly in patient populations with special circum-
stances, can be improved. Twelve experts from the
Asia-Pacific region formed the Asia-Pacific Panel Recom-
mendations for the Optimal Management of Chronic Hepa-
titis B (APPROACH) Working Group to review, challenge,
and assess relevant new data and inform future updates of
CHB treatment guidelines. The significance of and contro-
versy about reported findings were discussed and debated in
an expert meeting of the Working Group in Beijing, China, in
November 2008. This review paper attempts to identify areas
requiring improved CHB management and provide sugges-
tions for future guideline updates, with special emphasis on
treatment initiation and duration.
Keywords Chronic hepatitis B (CHB) 
Hepatitis B virus (HBV)  Nucleoside/nucleotide analog 
Interferon alfa  HBV DNA  ALT
Introduction
Chronic hepatitis B (CHB) is a major global health chal-
lenge and a leading cause of liver-related morbidity and
mortality within the Asia-Pacific region. To help guide
clinicians in their management of patients with CHB,
several regional and country expert associations have
developed treatment guidelines, incorporating advances in
both the understanding of the natural history of the disease
and the expanding range of therapeutic options [1–4].
Despite the availability of a large amount of new data on
CHB treatment, many issues remain unresolved [1, 5]. In
November 2008, 12 experts from the Asia-Pacific region
formed the Asia-Pacific Panel Recommendations for
the Optimal Management of Chronic Hepatitis B
(APPROACH) Working Group in an attempt to address
issues of ‘‘whom to treat and for how long?’’ The group
met at the Beijing Ditan Hospital, China, where relevant
data from recent studies were reviewed, assessed, and
challenged, with the significance of and controversy about
reported findings discussed and debated.
This paper aims to identify the challenges facing current
guidelines and discuss propositions for future CHB
guideline amendments, with the hope of enhancing anti-
viral treatment in the region.
Natural history of hepatitis B virus
The hepatitis B virus (HBV) causes chronic infection in
350–400 million people worldwide, 75% of whom are in
the Asia-Pacific region, with the majority acquiring the
infection at birth, or within the first 1–2 years of life [6, 7].
HBV is a known human carcinogen [8–10], with research
indicating it as a strong risk factor for cirrhosis and hepa-
tocellular carcinoma (HCC) [11, 12].
Three large-scale, long-term, prospective studies look-
ing at cohorts from Hong Kong [13], China [14], and
Taiwan [15] assessed the incidence of and risk factors for
cirrhosis, HCC, and death from liver disease among CHB
patients. Cohorts each included more than 1,000 subjects
and were followed for 7–11 years. All three studies came
to similar conclusions: HBV DNA concentration is the
most important predictor of HCC; the higher the HBV
DNA load, the higher the incidence of HCC. These find-
ings, along with data from similar risk prediction studies
[16], have led to all major treatment guidelines advocating
the elimination of viral replication as the primary aim of
CHB treatment [17].
HBV genotype has also been identified to be possibly
associated with an increased risk of HCC development [18,
19]. Important differences exist among HBV genotypes
and subgenotypes, which display different clinical and vi-
rological characteristics [20, 21]. Such differences may
affect the natural history and overall progression of the
disease, as well as response to treatment.
Genotypes B and C are predominant in Asia, charac-
teristically acquired through vertical transmission in the
perinatal period. They are distinct from HBV genotypes A
and D, acquired primarily in adulthood and predominant in
Western patients [18, 22]. There is increasing evidence that
HBV genotype C is associated with more severe liver
disease and an increased risk of HCC than HBV genotype
B [6, 19].
Despite these prognostic implications, HBV genotype
has no substantial impact on the therapeutic response to
oral nucleoside or nucleotide analogs [23, 24]. Further
studies are needed to understand the implications of HBV
genotype, and of particular interest is the need to adopt
different treatment initiation and cessation criteria for
patients with different genotypes and/or subgenotypes [13].
In addition, studies to address the role of some common
HBV variants in the development of HCC, such as pre-S
deletions and T1653 mutations, are warranted [25, 26].
Treatment initiation: ‘‘whom to treat?’’
The decision to commence treatment must balance the
likelihood of a sustained treatment response, with the
future risk of liver-related morbidity and mortality. Con-
sideration of further factors, including patient age, con-
current illness, medication compliance, liver disease
activity, likelihood of long-term benefit, and potential
therapeutic risks such as side effects, must be included as
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part of a risk–benefit analysis [27]. Cost, drug availability,
and the emergence of antiviral resistance are important
considerations of particular interest to the Asia-Pacific
region.
A large amount of new data have become available in
recent years, suggesting that conventional criteria for
treatment initiation based on existing disease progression
do not necessarily correlate with the future risk of disease
complications. There is therefore a need for a fresh
appraisal of the current evidence, with subsequent revisions
and updates for future guidelines.
Challenges and unresolved issues
Indications for treatment initiation are currently based on
three criteria: serum aminotransferase (alanine, ALT;
aspartate; AST) levels; serum HBV DNA levels; and his-
tological grade and stage.
Serum ALT level
Current Asian Pacific Association for the Study of the
Liver (APASL) recommendations indicate that treatment
initiation should be considered in patients with active HBV
replication and ALT levels at least twice the upper limit of
normal (ULN), but not in patients with persistently normal
or minimally elevated ALT levels, except where there is
evidence of advanced fibrosis or cirrhosis [1]. Such rec-
ommendations are based on the observation that the latter
subjects usually experience minimal histological changes
and respond poorly in terms of HBeAg seroconversion rate
to interferon (IFN) and oral antiviral therapy [1, 12].
Emerging data from several clinical studies indicate that
significant liver damage can occur in patients with high
viral loads and persistently normal ALT levels, particularly
if they are HBeAg negative [28, 29]. These patients are
easily excluded from treatment as a result of current ALT-
dependent treatment initiation criteria, particularly when
liver biopsy is not feasible.
ALT is now thought to be a relatively inaccurate marker
of liver fibrosis and may be a better indicator for necro-
inflammation, correlating poorly with the degree of liver
disease, particularly when only single measurements are
available. Recent studies suggest that patients with normal
serum ALT levels have no or minimal disease progression
[30, 31], whereas a substantial proportion of Asian patients
with minimally elevated ALT levels have significant his-
tological disease [28]. Another study reported that 23.7%
of Asian patients with persistently normal ALT levels had
significant histological findings including inflammation and
fibrosis [32]. Further studies indicate that a single, high-
normal ALT reading (between 0.5 and 1 times the ULN)
indicates a risk of advanced fibrosis in both HBeAg-posi-
tive and HBeAg-negative patients [33–35]. In a Hong
Kong longitudinal follow-up study, the cumulative risk of
disease complications, stratified according to ALT levels
on presentation, was found to be highest in patients with
ALT levels between one and two times the ULN. Patients
with ALT levels between 0.5 and 1 times the ULN also had
a significantly increased risk of complications [16], a claim
supported by a Korean population study [36].
Another concern of the inaccuracy of ALT as a marker
for liver fibrosis is the suitability of an ULN ‘‘threshold’’
due to variability in quoted reference ranges and hetero-
geneity within target populations. Several variables often
not accounted for when determining the ‘‘normal’’ ALT
range include age, fasting blood glucose, and serum tri-
glyceride levels, as well as differences in the commercial
assays used and the reference populations chosen by each
manufacturer to establish its reference range [37]. ALT
levels have further been shown to vary according to body
mass index (BMI). One study proposed that the current
ULN may be set too high, with values close to the
abnormal ULN value for someone with a low BMI [38].
Indirect evidence for this comes from cohort studies of
healthy patients, which indicated that the ULN should be
30 IU/mL for men and 19 IU/mL for women [37, 39].
Existing regional guidelines do not specify ULN values
for serum ALT, but APASL suggests ‘‘high normal’’
(ALT 0.5–1 times ULN) and ‘‘low normal’’ (ALT B0.5
times ULN) to help differentiate ULN values for serum
ALT. As ALT ULN varies greatly from laboratory to
laboratory, ranging from 36 U/L [40] to 60 U/L [41] in
published studies, standardization may not be appropriate.
For borderline ALT levels, alternative indicators such as
liver biopsy and histology are needed to evaluate the
extent of liver damage.
In light of these data, the most recent European Asso-
ciation for the Study of the Liver (EASL) treatment
guidelines suggest that abnormal ALT levels together with
HBV DNA levels of more than 2,000 IU/mL are sufficient
criteria for treatment commencement. A liver biopsy is
further recommended for determining the degree of necr-
oinflammation and fibrosis in such patients [3].
Serum HBV DNA level
Quantitation of serum HBV DNA previously utilized an
arbitrarily assigned value of 105 copies/mL as a criterion
for CHB treatment, based on a previous understanding of
CHB natural history, and lower sensitivity of previously
available viral load quantification assays [42]. HBV DNA
levels are currently quantified by polymerase chain reac-
tion (PCR) assays, which can detect HBV DNA levels as
low as 100 copies/mL.
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In the most recent APASL update, HBV DNA levels in
excess of 20,000 IU/mL (or 100,000 copies/mL) and
2,000 IU/mL (or 10,000 copies/mL), together with ALT
levels more than two times the ULN, have been proposed
as thresholds for treatment of HBeAg-positive and HBeAg-
negative hepatitis, respectively. While such HBV DNA
thresholds identify the majority of patients with active liver
disease, more than 10% of HBeAg-negative CHB patients
with persistently or transiently increased serum ALT levels
may have serum HBV DNA levels that fall below the rec-
ommended cutoff of 2,000 IU/mL [43]. In fact, no single
HBV DNA level can confidently differentiate patients with
active or inactive liver disease after HBeAg seroconversion
[44, 45]. Furthermore, a significant proportion of Asian
patients are at continued risk of liver complications despite
their HBV DNA levels falling below 10,000 copies/mL
[7, 46]. Patients with HBV DNA levels below 2,000 IU/mL
are also at a significantly higher risk of developing HCC than
uninfected patients [47]. Such studies reinforce the impact of
unsuppressed viral load on disease progression and suggest
that treatment initiation may need to be considered in
patients with lower levels of HBV DNA, especially among
patients with advanced fibrosis who have a significant risk of
developing HCC [48].
Histological grade
Current guidelines recommend liver biopsy to assess the
degree of necroinflammation and liver fibrosis prior to
treatment initiation in patients with increased HBV DNA
and/or minimally elevated ALT levels (1–2 times the ULN).
Liver biopsy is also recommended for patients older than
40 years, especially those with ‘‘high normal’’ ALT levels
[1]. Although liver biopsy remains the gold standard for
assessing hepatic fibrosis, its use has several limitations
including sampling error and intra- or interobserver sam-
pling variability [3, 49, 50]. Inadequate liver biopsy may
further pose misleading histological information that pre-
cludes cirrhotic patients from antiviral treatment [48]. In
addition, although the risk of severe complications is very
low (1 in 4,000–10,000), liver biopsy is associated with
undesirable procedural risks such as bleeding. Patients
potentially opt to avoid such invasive procedures, so there is
a need for a simple, reliable, noninvasive alternative, either
complementing or eliminating liver biopsy altogether
[3, 51].
APPROACH Working Group consensus
Current treatment initiation criteria potentially exclude
patients with a high risk of disease progression, particularly
patients with increased viral load and normal or mini-
mally elevated ALT levels who are probably not in the
immune-tolerant phase (i.e., [40 years of age). Serum
ALT, as one of the key conventional treatment initiation
criteria, does not satisfactorily reflect existing liver damage
sensitively or specifically and is a weaker risk factor than
viral load in predicting future liver disease complications.
While the current APASL recommended monitoring
approach toward immune-tolerant patients remains suit-
able, new methods are needed to evaluate liver histology in
the setting of normal ALT and high HBV DNA levels.
Future CHB treatment initiation recommendations should
be based on the primary treatment objective of preventing
liver injury, which may be achievable by treating before
complications arise, in the majority of patients.
Special populations
Decompensated patients must be treated as soon as possi-
ble, as should be patients with persistent disease activity,
signified by elevated ALT levels, and abnormal liver
function. Decompensated cirrhotic patients with detectable
HBV DNA by PCR should also be treated as early as
possible [2–4]. Patients with histological evidence of liver
damage as indicated by liver biopsy should be treated.
Asymptomatic patients with persistently low ALT levels
(normal or minimally elevated) and lack of clinical evi-
dence of liver damage (due to refusal of liver biopsy) may
also be treated, depending on the likelihood of disease
progression after consideration of additional risk factors
including age, gender, and family history of HCC.
Use of diagnostic tools
Evaluation of existing liver damage can be established
histologically using liver biopsy; however, further research
into the applicability of noninvasive tests in various HBV
patient populations is of particular interest. Several for-
mulae based on direct and indirect serum markers of
hepatic fibrosis focusing on chronic hepatitis C (CHC) have
been developed and evaluated [52] but may not be suitable
for CHB patients [53, 54]. Noninvasive predictive models
developed for CHB patients need further validation by
other groups [55–57].
Transient elastography, a diagnostic tool that has
recently been introduced as a novel, rapid, noninvasive,
and reproducible method to measure liver stiffness, is also
of interest. Meta-analyses of studies involving predomi-
nantly CHC patients have confirmed a high accuracy of
liver stiffness measurements (LSM) in predicting advanced
hepatic fibrosis and cirrhosis [58, 59]. The technique has
also been validated against histology in several studies
including CHB patients [60–62]. Despite the advantages of
this technique, its accuracy is inversely related to age and
BMI, with LSM failures reported in overweight patients
Hepatol Int (2010) 4:386–395 389
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with a BMI of more than 28 [63, 64]. In addition, major
changes in the inflammatory biochemical activity of serum
transaminases, induced by liver disease, may affect LSM
results [65]. Measurements of liver stiffness are also
technically difficult in particular individuals, including
patients with ascites and large vessels and patients with a
narrow intercostal space [51].
Predictors of disease progression
Future recommendations are needed to promote the adop-
tion of comprehensive assessments for clearly defined
common viral replication and liver function parameters,
prior to treatment initiation, and at various points during
treatment to determine efficacy. Assessments should pri-
marily consist of easily accessible tests including but not
limited to HBV DNA level, complete blood counts, pro-
thrombin time, biochemical tests, including AST and ALT,
c-glutamyl transpeptidase, alkaline phosphatase, and serum
albumin, and hepatic ultrasonography [1, 3]. Additional
testing for further parameters that are not easily accessible,
or affordable, such as HBV genotype, and precore and
basal core promoter mutations should be supplementary
until their role has been properly defined.
Estimation of the risk of disease progression might be
possible through the use of a ‘‘risk calculator’’ based on
common viral and liver parameters, as demonstrated in
other disease areas, including cardiovascular disease and
breast cancer [66, 67]. Several independent groups have
developed different risk prediction tools based on popula-
tion or hospital patient natural history cohorts to evaluate
the risk of disease progression [11, 13, 15, 16, 18, 68].
These tools include treatment assessment algorithms,
within which all potential risk factors, including gender,
age, HBeAg status, ALT elevation, cirrhosis status, HBV
genotype, and HBV DNA level, are incorporated. Scoring
systems translate these factors into risk scores that can be
further incorporated into risk function nomograms, offering
a means of making a fast, reasonable, and visually explicit
estimation of HCC risk [6, 69]. Such a ‘‘risk calculator’’
tool may help identify patients most benefiting from
immediate treatment intervention (e.g., a 40-year-old
individual with an 80% risk of HCC development in the
next 5 years), thereby supporting the objective to treat as
early as possible. This tool may also be particularly useful
in patients with asymptomatic disease.
A modified treatment paradigm to improve on current
patient risk stratification criteria is also important. In
addition, further representative studies for the validation of
risk calculation models as they evolve are needed and may,
in turn, inform the deciding cutoff levels for treatment
initiation in specific patient populations. Finally, there is a
requirement for future prospective studies to evaluate
antiviral treatment outcomes and likelihood of long-term
benefit of therapeutic intervention in specific patient pop-
ulations, particularly those in the immune-tolerant phase.
Treatment duration: ‘‘for how long?’’
Treatment duration is dictated by the desired treatment
goal, the ideal long-term goal of CHB therapy being the
complete suppression of HBV replication, leading to
improved quality of life and survival by preventing disease
progression, HCC, and death [3, 12, 70]. HBsAg seroc-
learance, indicating resolution of chronic infection, is the
optimal measure of treatment success but is rarely
achieved, even with pegylated IFN therapy. Approximately
0.5% of HBsAg carriers will clear HBsAg yearly; most will
develop anti-HBs [2]. Similarly, for nucleos(t)ide analogs,
only a small proportion of patients can achieve HBsAg
seroclearance. Most can achieve only viral suppression,
with virological rebound typically occurring upon treat-
ment cessation [71, 72]. Therefore, the issue whether
treatment with nucleos(t)ide analogs should be stopped
remains controversial.
Challenges and unresolved issues
Three conventional targets of antiviral therapy are
addressed within treatment guidelines: sustained undetect-
able HBV DNA levels by PCR; normalization of ALT
levels; and HBeAg seroconversion. More recently, rec-
ommendations have incorporated HBsAg seroclearance as
an end point for treatment cessation [3].
HBeAg seroconversion and HBeAg-positive patients
Current APASL guidelines state that oral antiviral treat-
ment cessation can be considered in HBeAg-positive
patients with HBeAg seroconversion and undetectable
HBV DNA levels on two consecutive occasions, with at
least 6-month intervals [1]. This is likely based on studies
that reported that 66.8 and 85% of spontaneous serocon-
verters showed sustained remission [35, 41]. Among
HBeAg seroconverters, a certain proportion may have a
sustained response with relapse rates of 27% reported,
shrinking to 11% in patients who had pretreatment HBV
DNA levels of 108 copies/mL or less [73]. However,
HBeAg seroconversion alone does not always signify a
sustained treatment response. While it has been suggested
that HBeAg positivity is associated with an increased risk
of HCC [74], more than 70% of patients with complica-
tions of cirrhosis and HCC are HBeAg-negative [16].
Finally, an earlier histological study showed no significant
390 Hepatol Int (2010) 4:386–395
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difference in the incidence of cirrhosis in HBeAg-positive
patients when compared with anti-HBe positive patients
[75].
Relapse following oral antiviral therapy is also frequent
in HBeAg-seroconverted patients. A Taiwanese study on
the cumulative development of HBeAg-negative CHB after
spontaneous HBeAg seroconversion found that the rate was
highest in the first few years following seroconversion,
reaching a plateau rate of 25% after approximately
10 years [41]. In a further follow-up study, reactivation of
hepatitis following treatment-induced seroconversion was
higher (45% of patients) and earlier than that of sponta-
neous seroconversion (30% of patients) [76]. The majority
of Korean patients are infected with HBV genotype C,
which is associated with high relapse levels following
lamivudine therapy [77]. Relapse rates after HBeAg sero-
conversion as high as 50% have been reported in these
patients [78]. These results suggest that not all patients
with HBeAg seroconversion have treatment-free remission
after stopping antiviral therapy, especially those among
Asian patients.
HBeAg-negative patients
Treatment cessation criteria are less clearly defined for
HBeAg-negative patients but include propositions that
treatment may be stopped if undetectable HBV DNA levels
have been established on three separate occasions, with 6-
month intervals [1]. While this is based on studies evalu-
ating treatment duration that suggested that up to 50% of
patients have maintained viral suppression following
treatment cessation [79–81], the challenge remains in
identifying those 50% of patients who would benefit from
continued therapy. A study of patients treated with lami-
vudine for 48 weeks reported similar results, with 73% of
patients having HBV DNA levels of\400 copies/mL upon
treatment cessation compared with 7% at the end of
24 weeks follow-up. Eight percent of patients who dis-
continued 48 weeks’ adefovir therapy had HBV DNA
levels of \1,000 copies/mL after 48 weeks’ follow-up
compared with 71% of patients who continued therapy
through 96 weeks [82, 83]. Consequently, most major
guidelines recommend long-term treatment of HBeAg-
negative patients or until sustained HBsAg seroclearance
has been demonstrated [2, 3].
HBsAg seroclearance
Various studies have shown that patients with spontaneous
HBsAg seroclearance have favorable biochemical, viro-
logical, and histological parameters, with markedly
improved necroinflammation and unchanged or regressed
liver fibrosis despite occult HBV infection [84, 85]. HBsAg
seroclearance usually confers favorable outcome if there is
no preexisting cirrhosis or viral superinfection, though
adverse complications may still occur. Furthermore,
HBsAg seroclearance before the age of 50 years is asso-
ciated with a lower risk of HCC than seroclearance at an
older age [86].
Nonetheless, spontaneous or treatment-induced HBsAg
seroclearance has long been considered a rare occur-
rence. Earlier studies reported the spontaneous annual
seroclearance rate in high endemic areas to be as low as
0.1 to 0.8% [87]. One recent follow-up study, however,
reported the cumulative seroclearance rate in asymp-
tomatic HBeAg-negative patients to be 40% after
25 years. It is worth noting that these patients initially
had undetectable HBV DNA and normal ALT levels
[87]. The occurrence of HBsAg seroclearance among
patients treated with long-term lamivudine is rare [88].
Among HBeAg-negative patients receiving 5 years of
adefovir treatment, approximately 5% achieved HBsAg
seroclearance [89]. For HBeAg-positive patients receiv-
ing 1 year of tenofovir treatment [72] and 2 years of
entecavir treatment [71], HBsAg seroclearance occurred
in 3 and 5% of patients, respectively. Adopting HBsAg
seroclearance as an end point in these cases means
potentially committing all patients to long-term treat-
ment. Further studies are needed to define patient groups
that have a high chance of HBsAg seroclearance by
antiviral treatment.
To complicate the picture further, the reliability of
HBsAg seroclearance as an end point has been ques-
tioned. One study has shown that 34% of Asian patients
who are HBsAg negative have detectable HBV DNA in
the liver despite serum levels being undetectable.
Another study reported detectable hepatic HBV DNA in
73% of HBsAg-negative Japanese patients, suggesting
that most patients continue to harbor HBV infection
[90, 91]. The long-term safety of nucleos(t)ide analogs is
also an important consideration, with the termination of
phase III clevudine trials due to myopathy an indication
of the danger in relying on 1-year clinical trial safety
profiles [92]. Adefovir and tenofovir can cause nephro-
toxicity, and telbivudine is associated with myopathy and
neuropathy [93, 94]. There are no serious reports of
lamivudine- and entecavir-related toxicity, but further
long-term studies are needed [92].
Treatment reinitiation
Defined treatment reinitiation criteria are not mentioned in
current CHB management guidelines. Moreover, current
re-treatment data are limited. Lamivudine re-treatment
studies have involved small patient cohorts (30–60
patients) manifesting high rates of drug resistance due to
Hepatol Int (2010) 4:386–395 391
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lamivudine’s low genetic barrier and intermediate potency
[95]. Recent studies on entecavir re-treatment appear more
promising, as undetectable HBV DNA levels (\300 copies/
mL) have been reported in 95% of HBeAg-negative
patients 3 years following treatment reinitiation [96].
APPROACH Working Group consensus
Treatment cessation criteria and clinical treatment end
points are difficult to define, and the best treatment end
point associated with the lowest risk of relapse remains
unclear.
The short-term target of antiviral therapy is currently
defined in many guidelines as maintained suppression of
HBV replication, with or without HBeAg seroconversion
[1, 12]. To avoid disease progression and to minimize
the risk of resistance, maintained viral suppression is
important, particularly in HBeAg-negative and HBeAg-
positive patients who have not yet achieved HBeAg
seroconversion. For seroconverted patients, recent data
have demonstrated that HBeAg seroconversion alone
may not signify freedom from risk of disease progression
and hepatitis relapse is common after treatment cessation
[40, 76, 77]. Current evidence suggests that HBsAg
seroclearance would be a preferred end point. In line
with recent EASL updates, existing guidelines need to be
revised to include sustainable suppression of HBV rep-
lication, with HBsAg seroclearance as the preferred
treatment end point; however, only a small proportion of
patients can achieve this end point with currently avail-
able oral nucleos(t)ide analogs.
Studies have suggested that serial measurements of
HBsAg concentration (titer) may be useful in determining
the ideal treatment end point [97], and the quantitation of
HBsAg may reflect the amount of covalently, closed, cir-
cular DNA inside the hepatocyte [98]. Future studies in this
area are of interest.
As the timing of treatment initiation may determine the
timing of HBsAg seroclearance [86], and ultimately affect
disease progression, the adoption of a preventative
approach to CHB treatment, identifying patients at risk
using thorough pretreatment evaluation criteria and initi-
ating treatment as early as possible, is strongly advocated.
Patient monitoring should continue to be mandatory
upon treatment cessation. While a recent study suggested
reinitiation of therapy is effective [96], data remain limited
and re-treatment criteria should be the same as those for
treatment initiation, as indicated in current APASL or
American Association for the Study of Liver Diseases
guidelines.
Finally, sustained HBeAg seroconversion may remain an
appropriate treatment goal for some patients, for example,
young HBeAg-positive patients without advanced disease.
As indicated in current guidelines, 6–12 months of consolida-
tion therapy and monitoring for relapse are crucial upon treat-
ment cessation in these patients [1–3]. Determining the risk of
disease progression and HCC development in these patients
through employment of a ‘‘risk calculator’’ may help answer the
crucial questions of ‘‘whom to treat’’ and ‘‘for how long’’?
Summary
Current challenges and considerations for future guidelines
amendments on ‘‘whom to treat’’ (Table 1) and ‘‘for how
long’’ (Table 2) are summarized below.
Table 1 Treatment initiation: whom to treat?
Current challenges
Current, stringent treatment initiation criteria may exclude HBV-
infected patients at high risk of HCC from treatment
Routine invasive liver biopsy poses clinical limitations, with variable
validity as well as potential patient compliance issues; alternative
noninvasive means of assessing liver fibrosis are required
APPROACH consensus
Symptomatic patients must be treated as early as possible
For asymptomatic patients refusing liver biopsy, noninvasive fibrosis
assessment should be considered and appropriate risk prediction/
calculation completed
Noninvasive fibrosis assessments should be further studied for routine
use, instead of liver biopsy, before decisions are made to initiate or
cease treatment
An improved treatment assessment algorithm or risk calculator,
incorporating all HCC risk factors and common liver parameters, is
required to aid hepatologists in redefining treatment initiation
criteria
Table 2 Treatment cessation: for how long?
Current challenges
Existing treatment end points have not been demonstrated to
sufficiently prevent reactivation or disease progression
Achieving treatment goals and defining appropriate clinical treatment
end points are often difficult
Treatment end points are constantly evolving as the understanding of
CHB natural history and factors associated with disease progression
improves
APPROACH consensus
HBsAg seroclearance is currently the single preferred treatment end
point for inclusion in future recommendations and more research is
required to determine its likelihood in specific patient populations
HBeAg seroconversion may continue to be an appropriate end point
accompanied by undetectable HBV DNA for certain patients with a
low, predetermined risk of HCC development
The duration of consolidated treatment after HBeAg seroconversion
requires further study with newer antiviral agents, and routine
patient monitoring for relapse should remain mandatory upon
treatment cessation in all CHB patients
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